View Single Post
Old 02-09-2009, 12:47 AM   #4
harrie
Senior Member
 
harrie's Avatar
 
Join Date: Mar 2007
Location: Hilo, Hawaii
Posts: 1,867
I have a copy of that full article (Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw) right here before me. Actually the research concerns oral biphosphonate, not IV (Zometa).
I wanted to go online to JADA to download the entire article and post it, but was unable to.
Basically the abstract says that oral biphosphantes were considered extremely low risk for ONJ in the past, but according to the abstract, there may be more of a risk then what was assumed.
Vicki, if you would like a copy of this entire article, you can either go to: http://jada.ada.org, then to the Jan 2009 issue.
Or...you can PM my with your address or FAX number and I would be happy to send you a copy of the article.

Also, on the bottom of the article, it gives contact info for Dr. Sedghizadenh. (ofc address as well as email)


Maryanne
__________________
*** MARYANNE *** aka HARRIECANARIE

1993: right side DCIS, lumpectomy, rads
1999: left side DCIS, lumpectomy, rads, tamoxifen

2006:
BRCA 2 positive
Stage I, invasive DCIS (6mm x 5mm)
Grade: intermediate
sentinal node biopsy: neg
HER2/neu amplified 4.7
ER+/PR+
TOPO II neg
Oncotype dx 20
Bilat mastectomy with DIEP flap reconstruction
oophorectomy

2007:
6 cycles TCH (taxotere, carboplatin, herceptin)
finished 1 yr herceptin 05/07
Arimidex, stopped after almost 1 yr
Femara

Last edited by harrie; 02-09-2009 at 12:53 AM..
harrie is offline   Reply With Quote